Article Text

Download PDFPDF

Primary care
Evidence evolves over time and should be based on data not opinion
  1. David Hawkes1,2,3
  1. 1Pharmacology and Therapeutics, University of Melbourne, Parkville, VIC 300, Australia
  2. 2Molecular Microbiology, VCS Foundation, Carlton, Victoria, Australia
  3. 3Pathology, University of Malaya, Kuala Lumpur, Malaysia
  1. Correspondence to Associate Professor David Hawkes, Pharmacology and Therapeutics, University of Melbourne, Parkville, VIC 3010, Australia; dhawkes{at}unimelb.edu.au

Statistics from Altmetric.com

Since the introduction of vaccines against certain types of human papillomavirus (HPV), there have been concerns voiced by those critical of the use of these vaccines. These arguments often follow similar patterns and use similar discussion approaches such as raising unfounded questions about safety or using ‘scary’ terms without context (eg, toxins). A recent manuscript by Little and Ward1 provided a representative example of the type of arguments made by vaccine critics that appear to have merit on first examination but which fail when more thoroughly investigated,2 and especially over time as the evidence base demonstrating vaccine safety increases.3 4

Little and Ward, like many other critics of the HPV vaccine, raise the issue of toxicity. In particular, they raise concerns about Polysorbate 80 and its relationship with infertility. They state that up to the age of 12, children receive a combined 0.8 mg of Polysorbate 80 administered through the Australian childhood vaccination schedule. This figure should not be considered a cause for concern, as 0.8 mg of Polysorbate 80 (the cumulative dose over 12 years) is >90 000 times lower than the acute exposure dose (based on rat intravenous LD50 of 1790 mg/kg5) for a 41 kg 12-year-old girl or >6700 times lower for a 3 kg infant. The animal study,6 …

View Full Text

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.